Provider adoption of pneumococcal conjugate vaccine and the impact of vaccine shortages

Ambulatory Pediatrics

Volumn 5, Issue 3, 2005, Pages 157-164

  Daley, Matthew F ^a,b,d   Crane, Lori A ^a,b   Beaty, Brenda L ^a   Barrow, Jennifer ^b   Pearson, Kellyn ^b   Stevenson, John M ^c   Berman, Stephen ^a,b   Kempe, Allison ^a,b  

^a UNIVERSITY OF COLORADO   (United States)

^b CHILDREN S HOSPITAL   (United States)

^c CENTERS FOR DIS CONTR AND PREV   (United States)

^d NONE   (United States)

Author keywords

Immunization; Pneumococcal conjugate vaccine; Provider attitudes; Vaccine shortages

Indexed keywords

PNEUMOCOCCUS VACCINE;

ARTICLE; CLINICAL PRACTICE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DRUG COST; DRUG MARKETING; DRUG SAFETY; FEMALE; FINANCE; GENERAL PRACTITIONER; HEALTH PRACTITIONER; HEALTH SURVEY; HUMAN; IMMUNIZATION; MALE; MULTIVARIATE ANALYSIS; PHYSICIAN ATTITUDE; POSTAL MAIL; PRESCHOOL CHILD; PRIVATE PRACTICE; REGISTER; RISK; RURAL AREA; STREPTOCOCCUS INFECTION; UNITED STATES; URBAN AREA;

EID: 20744445394     PISSN: 15301567     EISSN: None     Source Type: Journal    
DOI: 10.1367/A04-142R.1     Document Type: Article

References (60)

1. Centers for Disease Control and Prevention. Hepatitis B virus: a comprehensive strategy for eliminating transmission in the United States through universal childhood vaccination. Recommendations of the Immunization Practices Advisory Committee (ACIP). MMWR. 1991;40:1-25.
2. Yusuf HR, Coronado VG, Averhoff FA, et al. Progress in coverage with hepatitis B vaccine among US children, 1994-1997. Am J Public Health. 1999;89:1684-1689.
3. Centers for Disease Control and Prevention. National, state, and urban area vaccination coverage levels among children aged 19-35 months - United States, 1997. MMWR. 1998;47:547-554.
4. Centers for Disease Control and Prevention. National vaccination coverage levels among children aged 19-35 months - United States, 1998. MMWR. 1999;48:829-30.
5. Centers for Disease Control and Prevention. National, state, and urban area vaccination coverage levels among children aged 19-35 months - United States, 1999. MMWR. 2000;49:585-589.
6. Centers for Disease Control and Prevention. National, state, and urban area vaccination coverage levels among children aged 19-35 months - United States, 2000. MMWR. 2001;50:637-641.
7. Centers for Disease Control and Prevention. Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. 1996;45:1-36.
8. Centers for Disease Control and Prevention. National, state, and urban area vaccination coverage levels among children aged 19-35 months - United States, 2001. MMWR. 2002;51:664-666.
9. Centers for Disease Control and Prevention. National, state, and urban area vaccination levels among children aged 19-35 months - United States, 2002. MMWR. 2003;52:728-732.
10. Centers for Disease Control and Prevention. Rotavirus vaccine for the prevention of rotavirus gastroenteritis among children. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. 1999;48:1-20.
11. Centers for Disease Control and Prevention. Intussusception among recipients of rotavirus vaccine - United States, 1998-1999. MMWR. 1999;48:577-581.
12. Centers for Disease Control and Prevention. Withdrawal of rotavirus vaccine recommendation. MMWR. 1999;48:1007.
13. Sansom SL, Barker L, Corso PS, et al. Rotavirus vaccine and intussusception: how much risk will parents in the United States accept to obtain vaccine benefits? Am J Epidemiol. 2001;154: 1077-1085.
14. McPhillips HA, Davis RL, Marcuse EK, Taylor JA. The rotavirus vaccine's withdrawal and physicians' trust in vaccine safety mechanisms. Arch Pediatr Adolesc Med. 2001;155:1051-1056.
15. Iwamoto M, Saari TN, McMahon SR, et al. A survey of pediatricians on the reintroduction of a rotavirus vaccine. Pediatrics. 2003;112:e6.
16. Centers for Disease Control and Prevention. Preventing pneumococcal disease among infants and young children. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. 2000;49:1-35.
17. American Academy of Pediatrics. Committee on Infectious Diseases. Policy statement: recommendations for the prevention of pneumococcal infections, including the use of pneumococcal conjugate vaccine (Prevnar), pneumococcal polysaccharide vaccine, and antibiotic prophylaxis. Pediatrics. 2000;106:362-366.
18. Zimmerman RK. Pneumococcal conjugate vaccine for young children. Am Fam Physician. 2001;63:1991-1998.
19. Schaffer SJ, Szilagyi PG, Shone LP, et al. Physician perspectives regarding pneumococcal conjugate vaccine. Pediatrics. 2002;110: e68.
20. Davis MM, Ndiaye SM, Freed GL, Clark SJ. One-year uptake of pneumococcal conjugate vaccine: a national survey of family physicians and pediatricians. J Am Board Fam Pract. 2003;16: 363-371.
21. Davis MM, Andreae M, Freed GL. Physicians' early challenges related to the pneumococcal conjugate vaccine. Ambul Pediatr. 2001;1:302-305.
22. Lieu TA, Finkelstein JA, Adams MM, et al. Pediatricians' views on financial barriers and values for pneumococcal vaccine for children. Ambul Pediatr. 2002;2:358-366.
23. Freed GL, Davis MM, Andreae MC, et al. Reimbursement for Prevnar: a modern-day version of Hercules and the Hydra. Pediatrics. 2002;110:399-400.
24. Whitney CG, Farley MM, Hadler J, et al. Decline in invasive pneumococcal disease after the introduction of protem-polysaccharide conjugate vaccine. N Engl J Med. 2003;348:1737-1746.
25. Kaplan SL, Mason EO Jr, Wald ER, et al. Decrease of invasive pneumococcal infections in children among 8 children's hospitals in the United States after the introduction of the 7-valent pneumococcal conjugate vaccine. Pediatrics. 2004;113:443-449.
26. Flannery B, Schrag S, Bennett NM, et al. Impact of childhood vaccination on racial disparities in invasive Streptococcus pneumoniae infections. JAMA. 2004;291:2197-2203.
27. Black S, Shinefield H, Baxter R, et al. Postlicensure surveillance for pneumococcal invasive disease after use of heptavalent pneumococcal conjugate vaccine in Northern California Kaiser Permanente. Pediatr Infect Dis J. 2004;23:485-489.
28. Centers for Disease Control and Prevention. Decreased availability of pneumococcal conjugate vaccine. MMWR. 2001;50: 783-784.
29. Centers for Disease Control and Prevention. Updated recommendations on the use of pneumococcal conjugate vaccine in a setting of vaccine shortage - Advisory Committee on Immunization Practices. MMWR. 2001;50:1140-1142.
30. Centers for Disease Control and Prevention. Limited supply of pneumococcal conjugate vaccine. MMWR. 2003;52:1234.
31. Centers for Disease Control and Prevention. Updated recommendations on the use of pneumococcal conjugate vaccine: suspension of recommendation for third and fourth dose. MMWR. 2004; 53:177-178.
32. Centers for Disease Control and Prevention. Delayed supply of influenza vaccine and adjunct ACIP influenza vaccine recommendations for the 2000-01 influenza season. Advisory Committee on Immunization Practices. MMWR. 2000;49:619-622.
33. Centers for Disease Control and Prevention. Update on the supply of tetanus and diphtheria toxoids and of diphtheria and tetanus toxoids and acellular pertussis vaccine. MMWR. 2001;50: 189-190.
34. Centers for Disease Control and Prevention. Shortage of varicella and measles, mumps and rubella vaccines and interim recommendations from the Advisory Committee on Immunization Practices. MMWR. 2002;51:190-191.
35. Centers for Disease Control and Prevention. Update: supply of diphtheria and tetanus toxoids and acellular pertussis vaccine. MMWR. 2002;50:1159.
36. Renfrew BL, Kempe A, Lowery NE, et al. The impact of immunization record aggregation on up-to-date rates - implications for immunization registries in rural areas. J Rural Health. 2001;17:122-126.
37. Kempe A, Steiner JF, Renfrew BL, et al. How much does a regional immunization registry increase documented immunization rates at primary care sites in rural Colorado? Ambul Pediatr. 2001;1:213-216.
38. Daley MF, Steiner JF, Brayden RM, et al. Immunization registry-based recall for a new vaccine. Ambul Pediatr. 2002;2:438-443.
39. Janz NK, Champion VL, Strecher VJ. The Health Belief Model. In: Glanz K, Rimer BK, Lewis FM, eds. Health Behavior and Health Education: Theory, Research, and Practice. 3rd Edition ed. San Francisco, Calif: Jossey-Bass; 2002:45-66.
40. Zimmerman RK, Bradford BJ, Janosky JE, et al. Barriers to measles and pertussis immunization: the knowledge and attitudes of Pennsylvania primary care physicians. Am J Prev Med. 1997; 13:89-97.
41. Zimmerman RK, Schlesselman JJ, Mieczkowski TA, et al. Physician concerns about vaccine adverse effects and potential litigation. Arch Pediatr Adolesc Med. 1998;152:12-29.
42. Zimmerman RK, Mieczkowski TA, Mainzer HM, et al. Understanding physician agreement with varicella immunization guidelines. Prev Med. 2002;35:135-142.
43. Ehresmann KR, Mills WA, Loewenson PR, Moore KA. Attitudes and practices regarding varicella vaccination among physicians in Minnesota: implications for public health and provider education. Am J Public Health. 2000;90:1917-1920.
44. Cooper A, Yusuf H, Rodewald L, et al. Attitudes, practices, and preferences of pediatricians regarding initiation of hepatitis B immunization at birth. Pediatrics. 2001;108:e98.
45. Freed GL, Davis MM, Clark SJ. Variation in public and private supply of pneumococcal conjugate vaccine during a shortage. JAMA. 2003;289:575-578.
46. Centers for Disease Control and Prevention. Pneumococcal conjugate vaccine shortage resolved. MMWR. 2003;52:446-447.
47. Nunnally JC. Assessment of reliability. In: Psychometric Theory. 2nd ed. New York, NY: McGraw-Hill Inc; 1978:225-255.
48. Schafer JL. Analysis of Incomplete Multivariate Data. London, UK: Chapman & Hall; 1997.
49. Zhang J, Yu KF. What's the relative risk? A method of correcting the odds ratio in cohort studies of common outcomes. JAMA. 1998;280:1690-1691.
50. Forthofer R, Lee E. Introduction to biostatistics: a guide to design, analysis, and discovery. San Diego, Calif: Academic Press Inc; 1995.
51. Freed GL, Bordley WC, Clark SJ, Konrad TR. Universal hepatitis B immunization of infants: reactions of pediatricians and family physicians over time. Pediatrics. 1994;93:747-751.
52. Freed GL, Freeman VA, Clark SJ, et al. Pediatrician and family physician agreement with and adoption of universal hepatitis B immunization. J Fam Pract. 1996;42:587-592.
53. Zimmerman RK, Mieczkowski TA. How important is early childhood hepatitis B vaccination? A survey of primary care physicians. J Fam Pract. 1998;47:370-374.
54. Newman RD, Taylor JA. Reactions of pediatricians to the recommendation for universal varicella vaccination. Arch Pediatr Adolesc Med. 1998;152:792-796.
55. Schaffer SJ, Bruno S. Varicella immunization practices and the factors that influence them. Arch Pediatr Adolesc Med. 1999; 153:357-362.
56. Hueston WJ, Meade RL, Mainous AG 3rd. Childhood immunization practices of primary care physicians. Arch Fam Med. 1992; 1:225-228.
57. Deutchman M, Brayden R, Siegel C, et al. Childhood immunization practices in rural family and general practices: current practices, perceived barriers and strategies for improvement. Ambul Child Health. 2000;6:181-189.
58. Pelton SI, Dagan R, Gaines BM, et al. Pneumococcal conjugate vaccines: proceedings from an interactive symposium at the 41st Imerscience Conference on Antimicrobial Agents and Chemotherapy. Vaccine. 2003;21:1562-1571.
59. Asch DA, Jedrziewski MK, Christakis NA. Response rates to mail surveys published in medical journals. J Clin Epidemiol. 1997;50:1129-1136.
60. Cummings SM, Savitz LA, Konrad TR. Reported response rates to mailed physician questionnaires. Health Serv Res. 2001;35: 1347-1355.